--Honor recognizes excellence in ChIP, DNA methylation innovation and service--
SAN DIEGO, Oct. 23 /PRNewswire/ -- Genpathway, Inc. announced today that the company has received the 2008 Frost & Sullivan North American Services in Drug Discovery Technologies Healthcare Innovation Award.
The award recognizes Genpathway for providing superior services for chromatin immunoprecipitation (ChIP) and DNA methylation assays that directly contribute to discoveries in gene regulation, epigenetics, and gene transcription.
"Frost & Sullivan recognizes Genpathway for its outstanding efforts to provide researchers an efficient and economical solution to fast-track notoriously difficult ChIP procedures," explained Frost & Sullivan industry analyst Christianne Bird. "As the recognized experts in ChIP, Genpathway consistently is the first to deliver cutting-edge technologies to the market and teams with top technology providers to offer the newest ChIP techniques available. For its commitment to providing innovative services to advance life sciences research and drug discovery and its position as the leader in its field, Frost & Sullivan is pleased to present Genpathway the 2008 North America Services in Drug Discovery Technologies Healthcare Innovation Award."
"Genpathway is honored to be recognized with this prestigious award from Frost & Sullivan," said Mary Harper, PhD, Chief Scientific Officer of Genpathway. "As interest in and demand for ChIP and DNA methylation assays continues to expand rapidly, our goal is to provide researchers across a broad range of disease areas and research fields a fast-track to discovery using our whole-genome assays. Genpathway's complete ChIP and DNA IP solutions are proving highly valuable for understanding gene regulation and genetic pathways by studying transcription factor binding, gene transcription, and epigenetic events such as DNA methylation and histone modifications."
Frost & Sullivan presents its Annual Award for Innovation in Healthcare to the company that has introduced truly innovative products, practices, or ideas within its industry. The award recognizes the company's innovative contributions that make it possible to envision a new level of care in the diagnosis, treatment, and management of disease, leading to better outcomes and quality of life for patients; or that lead to improvements in the tools that clinicians, diagnosticians, researchers, and healthcare administrators have at their disposal to improve quality and efficiency in provision of healthcare services. The selection of this award is based on interviews and primary market analysis conducted by Frost & Sullivan's industry analyst team.
About Genpathway (http://www.genpathway.com)
Genpathway is a pharmacogenomics company that provides specialized drug discovery, research, and development services and develops novel diagnostic biomarkers that predict drug responses, enabling personalized treatments. The company applies its proprietary chromatin and methylated DNA immunoprecipitation (ChIP) technology to understand gene regulation and genetic pathways by studying transcription factor binding, gene transcription, and epigenetic events such as DNA methylation and histone modifications. Based on the information gained from its technology, Genpathway is developing and commercializing a broad portfolio of clinically validated molecular diagnostic products and services that will enable the accurate selection of specific drugs to efficaciously treat individuals with cancer, immune disorders, and other serious diseases.
About Frost & Sullivan (http://www.frost.com)
Frost & Sullivan, the Growth Partnership Company, partners with clients
to accelerate their growth. The company's TEAM Research, Growth Consulting,
and Growth Team Membership(TM) empower clients to create a growth-focused
culture that generates, evaluates, and implements effective growth
strategies. Frost & Sullivan employs over 45 years of experience in
partnering with Global 1000 companies, emerging businesses, and the
investment community from more than 30 offices on six continents. For more
information about Frost & Sullivan's Growth Partnership Services, visit
Copyright©2008 PR Newswire.
All rights reserved